Acumen Pharmaceuticals (ABOS) Cash & Current Investments (2020 - 2026)

Acumen Pharmaceuticals' Cash & Current Investments history runs 7 years deep, the most recent figure standing at $128.4 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 13.91% year-over-year to $128.4 million; the TTM figure through Mar 2026 stood at $128.4 million (down 13.91% YoY), while the FY2025 annual figure was $116.9 million, down 31.75% from the prior year.
• Cash & Current Investments came in at $128.4 million for Q1 2026 at Acumen Pharmaceuticals, up from $116.9 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $260.1 million in Q2 2024 to a low of $116.9 million in Q4 2025.
• A 5-year average of $179.3 million and a median of $176.6 million in 2022 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments soared 175.99% in 2022 and plunged 44.88% in 2025, its largest moves.
• Acumen Pharmaceuticals' Cash & Current Investments stood at $176.6 million in 2022, then jumped by 37.5% to $242.8 million in 2023, then fell by 29.49% to $171.2 million in 2024, then sank by 31.75% to $116.9 million in 2025, then grew by 9.87% to $128.4 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $128.4 million, $116.9 million, and $126.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison